ASCEMBL: Recent Data Updates for Asciminib in CML

Opinion
Video

Charles A. Schiffer, MD, reviews clinical trial data for asciminib in chronic myeloid leukemia and highlights financial toxicity concerns.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content
Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
August 15th 2025
Article
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
August 15th 2025
Podcast
Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.

Pirtobrutinib Yields Noninferior ORR Vs Ibrutinib in CLL/SLL

Russ Conroy
August 15th 2025
Article
Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
August 15th 2025
Podcast
Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.

Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers

Russ Conroy
August 15th 2025
Article
Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

Tim Cortese
August 15th 2025
Article